Denosumab-Nxxp: uses, dosing, side effects & brands
Denosumab-Nxxp is a medicine sold in the U.S. under 2 brand and generic names, for postmenopausal osteoporosis. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Postmenopausal Osteoporosis
- Available as
- Injectable
- Sold as
- 2 products — Bildyos and Bilprevda
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How denosumab-nxxp is dosed
From the FDA label for Bildyos (application BLA761444). Other denosumab-nxxp products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Bilprevda should be administered by a healthcare provider. ( 2.1 ) Bilprevda is intended for subcutaneous route only and should not be administered intravenously, intramuscularly, or intradermally. ( 2.1 ) Multiple Myeloma and Bone Metastasis from Solid Tumors: Administer 120 mg every 4 weeks as a subcutaneous injection in the upper arm, upper thigh, or abdomen. ( 2.2 ) Giant Cell Tumor of Bone: Administer 120 mg every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy. Administer subcutaneously in the upper arm, upper thigh, or abdomen. ( 2.3 ) Administer calcium and vitamin D as necessary to treat or prevent hypocalcemia. ( 2.2 , 2.3 ) Hypercalcemia of Malignancy: Administer 120 mg every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy. Administer subcutaneously in the upper arm, upper thigh, or abdomen. ( 2.4 ) 2.1 Important Administration Instructions Bilprevda should be administered by a healthcare provider. Bilprevda is intended for subcutaneous route only and should not be administered intravenously, intramuscularly, or intradermally. 2.2 Multiple Myeloma and Bone Metastasis from Solid Tumors The recommended dose of Bilprevda is 120 mg administered as a subcutaneous injection every 4 weeks in the upper arm, upper thigh, or abdomen. Administer calcium and vitamin D as necessary to treat or prevent…
Denosumab-Nxxp side effects
The following adverse reactions are discussed below and elsewhere in the labeling: Hypersensitivity [see Warnings and Precautions ( 5.2 )] Hypocalcemia [see Warnings and Precautions ( 5.3 ) and Use in Specific Populations ( 8.6 )] Osteonecrosis of the Jaw [see Warnings and Precautions ( 5.4 )] Atypical Subtrochanteric and Diaphyseal Femoral Fracture [see Warnings and Precautions ( 5.5 )] Hypercalcemia following treatment discontinuation in patients with giant cell tumor of bone and in patients with growing skeletons [see Warnings and Precautions ( 5.6 ) and Use in Specific Populations ( 8.4 )] Multiple vertebral fractures (MVF) following treatment discontinuation [see Warnings and Precautions ( 5.7 )] Bone Metastasis from Solid Tumors: Most common adverse reactions (≥ 25%) were fatigue/asthenia, hypophosphatemia, and nausea. ( 6.1 ) Multiple Myeloma: Most common adverse reactions (≥ 10%) were diarrhea, nausea, anemia, back pain, thrombocytopenia, peripheral edema, hypocalcemia, upper respiratory tract infection, rash, and headache. ( 6.1 ) Giant Cell Tumor of Bone: Most common adverse reactions (≥ 10%) were arthralgia, headache, nausea, back pain, fatigue, and pain in extremity. ( 6.1 ) Hypercalcemia of Malignancy: Most common adverse reactions (> 20%) were nausea, dyspnea, decreased appetite, headache, peripheral edema, vomiting, anemia, constipation, and diarrhea. ( 6.1 ) To…
Who shouldn’t take denosumab-nxxp
Hypocalcemia. ( 4.1 ) Known clinically significant hypersensitivity to denosumab products. ( 4.2 ) 4.1 Hypocalcemia Pre-existing hypocalcemia must be corrected prior to initiating therapy with Bilprevda [see Warnings and Precautions ( 5.3 )] . 4.2 Hypersensitivity Bilprevda is contraindicated in patients with known clinically significant hypersensitivity to denosumab products [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.2 )] .
Every denosumab-nxxp product we track (2)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|
| 1 | Not yet rated | Prescription | Injectable | No data | — | View → | |
| 2 | Not yet rated | Prescription | Injectable | No data | — | View → |
Related calculators
Frequently asked questions
What is denosumab-nxxp?
Bildyos (Denosumab-Nxxp) is a medication used to treat Postmenopausal Osteoporosis.
Can you take denosumab-nxxp with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run denosumab-nxxp against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is denosumab-nxxp sold under?
We track 2 denosumab-nxxp-containing products in the U.S.: Bildyos and Bilprevda. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does denosumab-nxxp come in?
Across the brands we track, denosumab-nxxp is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic denosumab-nxxp?
We do not currently list a generic-labelled denosumab-nxxp product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Denosumab-Nxxp: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/denosumab-nxxp
- MLA
- “Denosumab-Nxxp: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/denosumab-nxxp.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for denosumab-nxxp on DailyMed (NIH) ↗.